Transvaginal Mesh Versus Native Tissue Repair for Anterior and Apical Pelvic Organ Prolapse

IF 2 Q2 OBSTETRICS & GYNECOLOGY
Eric R. Sokol MD, PhD , Le Mai Tu MD, PhD , Sherry L. Thomas MD , Ty B. Erickson MD , Jan-Paul W.R. Roovers
{"title":"Transvaginal Mesh Versus Native Tissue Repair for Anterior and Apical Pelvic Organ Prolapse","authors":"Eric R. Sokol MD, PhD ,&nbsp;Le Mai Tu MD, PhD ,&nbsp;Sherry L. Thomas MD ,&nbsp;Ty B. Erickson MD ,&nbsp;Jan-Paul W.R. Roovers","doi":"10.1016/j.jogc.2024.102658","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This prospective comparative cohort study aims to evaluate the safety and efficacy of transvaginal mesh compared to native tissue repair (NTR) in the surgical correction of anterior and apical compartment pelvic organ prolapse (POP) over a 36-month follow-up period.</div></div><div><h3>Methods</h3><div>Prospective comparative cohort study to prove superiority for efficacy and non-inferiority for serious adverse events (SAEs). The setting was 49 sites across the United States, Canada, Europe, and Australia. Women with bothersome POP symptoms indicated for vaginal surgery with pelvic organ prolapse quantification (POP-Q) scores of Ba ≥0 and C ≥ -1/2 total vaginal length were included. Interventions included vaginal NTR or single-incision transvaginal mesh based on shared decision-making. POP recurrence, the primary efficacy endpoint, was defined as anatomical prolapse beyond the hymenal ring, subjective perception of protrusion or bulge, or retreatment in the target compartment. The primary safety endpoint consisted of the proportion of device and/or procedure-related SAEs in the target compartment. Secondary endpoints included surgical parameters, quality of life, postoperative pain, and sexual function.</div></div><div><h3>Results</h3><div>POP recurrence rate at 12 months was 13.1% in the Mesh-arm and 11.5% in the NTR-arm (<em>P</em> = 0.44). The primary safety endpoint was met, with the Mesh-arm demonstrating statistically non-inferior outcomes compared to the NTR-arm in the incidence of device and/or procedure-related SAEs in the target compartment through 12 months (<em>P</em> &lt; 0.01). At 36 months, the surgical POP recurrence rate was 26.7% in the Mesh-arm and 27.0% in the NTR-arm.</div></div><div><h3>Conclusions</h3><div>At 12- and 36-month follow-up, transvaginal mesh was not superior, but non-inferior in terms of efficacy and safety when compared to NTR for patients with combined anterior and apical compartment prolapse.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of obstetrics and gynaecology Canada","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S170121632400481X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

This prospective comparative cohort study aims to evaluate the safety and efficacy of transvaginal mesh compared to native tissue repair (NTR) in the surgical correction of anterior and apical compartment pelvic organ prolapse (POP) over a 36-month follow-up period.

Methods

Prospective comparative cohort study to prove superiority for efficacy and non-inferiority for serious adverse events (SAEs). The setting was 49 sites across the United States, Canada, Europe, and Australia. Women with bothersome POP symptoms indicated for vaginal surgery with pelvic organ prolapse quantification (POP-Q) scores of Ba ≥0 and C ≥ -1/2 total vaginal length were included. Interventions included vaginal NTR or single-incision transvaginal mesh based on shared decision-making. POP recurrence, the primary efficacy endpoint, was defined as anatomical prolapse beyond the hymenal ring, subjective perception of protrusion or bulge, or retreatment in the target compartment. The primary safety endpoint consisted of the proportion of device and/or procedure-related SAEs in the target compartment. Secondary endpoints included surgical parameters, quality of life, postoperative pain, and sexual function.

Results

POP recurrence rate at 12 months was 13.1% in the Mesh-arm and 11.5% in the NTR-arm (P = 0.44). The primary safety endpoint was met, with the Mesh-arm demonstrating statistically non-inferior outcomes compared to the NTR-arm in the incidence of device and/or procedure-related SAEs in the target compartment through 12 months (P < 0.01). At 36 months, the surgical POP recurrence rate was 26.7% in the Mesh-arm and 27.0% in the NTR-arm.

Conclusions

At 12- and 36-month follow-up, transvaginal mesh was not superior, but non-inferior in terms of efficacy and safety when compared to NTR for patients with combined anterior and apical compartment prolapse.
经阴道网片与原生组织修复术治疗前部和顶部盆腔器官脱垂。
研究目的这项前瞻性队列比较研究旨在评估经阴道网片与原生组织修复术(NTR)相比,在为期 36 个月的随访期内,在手术矫正前壁和顶壁盆腔器官脱垂(POP)方面的安全性和有效性:方法:前瞻性队列比较研究,以证明疗效的优越性和严重不良事件(SAE)的非劣性。研究地点位于美国、加拿大、欧洲和澳大利亚的 49 个地点。研究对象包括有POP症状且POP-Q评分Ba≥0、C≥-1/2 TVL、有阴道手术指征的妇女。根据共同决策,干预措施包括阴道NTR或单切口经阴道网片。POP复发是主要的疗效终点,定义为超过处女膜环的解剖学脱垂、主观感觉的突出或隆起,或目标区的再治疗。主要安全性终点包括目标腔室中发生器械和/或手术相关 SAE 的比例。次要终点包括手术参数、生活质量、术后疼痛和性功能:12个月时,Mesh-arm和NTR-arm的POP复发率分别为13.1%和11.5%(P = 0.44)。Mesh治疗组达到了主要安全性终点,与NTR治疗组相比,Mesh治疗组在12个月内靶区的器械和/或手术相关SAE发生率在统计学上不劣于NTR治疗组(P < 0.01)。36个月时,Mesh臂的手术POP复发率为26.7%,NTR臂为27.0%:结论:在12个月和36个月的随访中,经阴道网片在治疗合并前壁和顶端脱垂患者的疗效和安全性方面与原生组织修复术相比没有优势,但没有劣势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.30
自引率
5.60%
发文量
302
审稿时长
32 days
期刊介绍: Journal of Obstetrics and Gynaecology Canada (JOGC) is Canada"s peer-reviewed journal of obstetrics, gynaecology, and women"s health. Each monthly issue contains original research articles, reviews, case reports, commentaries, and editorials on all aspects of reproductive health. JOGC is the original publication source of evidence-based clinical guidelines, committee opinions, and policy statements that derive from standing or ad hoc committees of the Society of Obstetricians and Gynaecologists of Canada. JOGC is included in the National Library of Medicine"s MEDLINE database, and abstracts from JOGC are accessible on PubMed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信